BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 22946493)

  • 1. Erwinia asparaginase in pediatric acute lymphoblastic leukemia.
    Salzer W; Seibel N; Smith M
    Expert Opin Biol Ther; 2012 Oct; 12(10):1407-14. PubMed ID: 22946493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erwinia asparaginase: coming closer to an understanding of its use in pediatric acute lymphoblastic leukemia?
    Maloney KW
    Pediatr Blood Cancer; 2010 Feb; 54(2):189-90. PubMed ID: 19967774
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.
    Plourde PV; Jeha S; Hijiya N; Keller FG; Silverman LB; Rheingold SR; Dreyer ZE; Dahl GV; Mercedes T; Lai C; Corn T
    Pediatr Blood Cancer; 2014 Jul; 61(7):1232-8. PubMed ID: 24436152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
    Keating GM
    BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemia.
    Salzer WL; Asselin BL; Plourde PV; Corn T; Hunger SP
    Ann N Y Acad Sci; 2014 Nov; 1329():81-92. PubMed ID: 25098829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.
    Vrooman LM; Supko JG; Neuberg DS; Asselin BL; Athale UH; Clavell L; Kelly KM; Laverdière C; Michon B; Schorin M; Cohen HJ; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2010 Feb; 54(2):199-205. PubMed ID: 19672973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
    Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
    Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
    Boos J
    Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].
    Takahashi H; Koh K; Kato M; Isobe K; Yasui N; Mori M; Akiyama K; Kikuchi A; Hanada R
    Rinsho Ketsueki; 2013 Apr; 54(4):370-7. PubMed ID: 23666219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
    Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
    Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
    Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
    Figueiredo L; Cole PD; Drachtman RA
    Expert Rev Hematol; 2016 Mar; 9(3):227-34. PubMed ID: 26765930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
    Ogawa C; Taguchi F; Goto H; Koh K; Tomizawa D; Ohara A; Manabe A
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28244643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
    Wacker P; Land VJ; Camitta BM; Kurtzberg J; Pullen J; Harris MB; Shuster JJ;
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):627-32. PubMed ID: 17805038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Update on L-asparaginase treatment in paediatrics].
    Moscardó Guilleme C; Fernández Delgado R; Sevilla Navarro J; Astigarraga Aguirre I; Rives Solà S; Sánchez de Toledo Codina J; Fuster Soler JL; Parra Ramirez L; Molina Garicaño J; González Martínez B; Madero López L
    An Pediatr (Barc); 2013 Nov; 79(5):329.e1-329.e11. PubMed ID: 23727426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
    Castaman G; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):57-60. PubMed ID: 8039761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
    Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
    Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.